Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Viskase Holdings, Inc.: Board approved and filed Certificate of Designation of Series A-2 Junior Participating Preferred Stock in connection with Section 382 Rights Agreement (effective 2026-05-05).
- Change
- charter amendment
- Effective
- 2026-05-05
Exact text from the filing
In connection with the adoption of the Section 382 Rights Agreement, the Board approved a Certificate of Designation of Series A-2 Junior Participating Preferred Stock of Viskase Holdings, Inc. (the “Certificate of Designation”). The Certificate of Designation was filed with the Secretary of the State of Delaware on May 5, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Viskase Holdings, Inc. entered into Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (effective 2026-05-05).
- Action
- entry
- Counterparty
- Continental Stock Transfer & Trust Company
- Effective
- 2026-05-05
Exact text from the filing
On April 30, 2026 (the “Rights Dividend Declaration Date”), the Board of Directors (the “Board”) of Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “Company”) adopted a Section 382 Rights Agreement (the “Section 382 Rights Agreement”)
View on SEC.gov